Improved and optimized drug repurposing for the SARS-CoV-2 pandemic.

The active global SARS-CoV-2 pandemic caused more than 426 million cases and 5.8 million deaths worldwide. The development of completely new drugs for such a novel disease is a challenging, time intensive process.